NASDAQ · AMRX
Healthcare · Drug Manufacturers - Specialty & Generic
$16.65
Up+$0.22 (+1.32%)
Updated Sep 16, 2026, 2:11 PM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AMRX closed at $16.65 after 20 trading sessions, down 8.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $17.22 | $17.25 | $16.58 | $16.65 | 1.79M |
| Sep 14, 2026 | $17.11 | $17.30 | $16.98 | $17.22 | 1.6M |
| Sep 11, 2026 | $17.00 | $17.11 | $16.73 | $17.01 | 1.16M |
| Sep 10, 2026 | $17.22 | $17.3094 | $16.825 | $16.87 | 1.04M |
| Sep 9, 2026 | $17.27 | $17.36 | $17.08 | $17.25 | 1.47M |
| Sep 8, 2026 | $17.27 | $17.395 | $16.98 | $17.05 | 2.04M |
| Sep 4, 2026 | $17.57 | $17.705 | $17.37 | $17.44 | 1.44M |
| Sep 3, 2026 | $18.25 | $18.26 | $17.735 | $17.87 | 2.75M |
| Sep 2, 2026 | $17.90 | $18.32 | $17.61 | $18.06 | 2.61M |
| Sep 1, 2026 | $17.57 | $17.99 | $17.40 | $17.68 | 1.36M |
| Aug 31, 2026 | $17.46 | $17.615 | $17.175 | $17.47 | 1.74M |
| Aug 28, 2026 | $18.04 | $18.10 | $17.47 | $17.54 | 1.15M |
| Aug 27, 2026 | $17.82 | $18.11 | $17.60 | $18.01 | 1.1M |
| Aug 26, 2026 | $18.00 | $18.12 | $17.85 | $17.99 | 1.21M |
| Aug 25, 2026 | $17.78 | $17.96 | $17.61 | $17.92 | 1.14M |
| Aug 24, 2026 | $17.81 | $17.92 | $17.6101 | $17.78 | 1.79M |
| Aug 21, 2026 | $17.99 | $18.12 | $17.77 | $17.91 | 1.37M |
| Aug 20, 2026 | $17.87 | $18.025 | $17.7338 | $17.90 | 1.25M |
| Aug 19, 2026 | $18.51 | $18.58 | $17.95 | $18.11 | 1.47M |
| Aug 18, 2026 | $18.45 | $18.76 | $18.02 | $18.19 | 2.03M |
The latest Smart Investors Daily articles mentioning AMRX.
AMRX research
Company profile and research snapshot.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Aug 26, 2026 | JP Morgan | Overweight | — |
| Aug 3, 2026 | UBS | Buy | — |
| Jul 15, 2026 | UBS | Buy | — |
| May 20, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Benzinga · Sep 9, 2026
Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.
Yahoo · Sep 5, 2026
In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...
Yahoo · Sep 4, 2026
On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]
Yahoo · Sep 4, 2026
Amneal Pharmaceuticals is back in focus after analysts lifted fair value from US$20.25 to US$21.00 per share, reflecting updated assumptions in recent models. Much of this shift lines up with Street research that leans positive on growth, execution, and the potential from new product launches and a broader portfolio. Keep reading to see what is changing in the narrative around Amneal Pharmaceuticals and how you can track those moving parts over time. Stay updated as the Fair Value for Amneal...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AMRX.
